ABCL: AbCellera Corp Price to Sales
Karl Hansen's team possesses impeccable scientific authority, although R&D return timelines remain lengthy. The current P/S multiple on this GURU.Markets chart visualizes the valuation trend, where 55.80 captures the magnitude of this parameter. AI technologies are accelerating antibody discovery for pharma behemoths, while the founder's control via super-voting shares ensures stable management of the AbCellera Biologics (ABCL) platform.
Analytical breakdowns for AbCellera Corp (ABCL)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ABCL - Company Net Income|Expected Net Income AbCellera Biologics|ABCL - P/E Multiple|Forward P/E Multiple AbCellera|ABCL - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation AbCellera Corp|ABCL - Operating profit EBITDA|Earnings per share for the last twelve months AbCellera|ABCL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months abcellera.com|ABCL - Earnings per share growth in current year|Expected net earnings per share growth next year AbCellera Biologics
- issuer revenue and sales details:
Fundamental company analysis:abcellera.com ABCL
The P/S ratio determines the market value of AbCellera Biologics (ABCL) relative to its annual revenue, allowing for an assessment of the asset's overvaluation without the influence of debt load. By analyzing the price-to-sales metric, an investor can see how the high reputation of Carl Hansen's team and the potential of the antibody platform justify current multiples given the prolonged payback cycles of scientific research.
Competitors of AbCellera Biologics
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|KNSA (kiniksa.com) - Price-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Market Cap to Revenue Adaptive Biotech (ADPT)|P/S Multiple CLDX|AUPH - Price to Sales|Price-to-Revenue Ratio BioCryst BCRX|veratx.com - Price-to-Revenue Ratio|DNTH - Price-to-Revenue Ratio|PHVS: Price-to-Revenue Ratio|TRML: P/S Multiple|Price to Sales Precigen Corp (PGEN)|Price-to-Revenue Ratio Pharming Group N.V.|NKTR: Market Capitalization-to-Revenue Ratio|P/S Multiple UPB|P/S Multiple Zenas Bio (ZBIO)|Immunome Corp - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOSS|KalVista Pharmaceuticals - P/S Multiple|SEPN: Price-to-Revenue Ratio|PVLA: P/S Multiple|SVRA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|Price to Sales AnaptysBio Inc. ANAB|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|Price-to-Revenue Ratio ENGN (engene.com)|Price-to-Revenue Ratio RAPT Therapeutics RAPT|Aerovate Therapeutics, Inc. (JBIO) - Price to Sales|Aclaris - P/S Multiple|Price-to-Revenue Multiple Kyverna Therapeutics, Inc (KYTX)|TLSA: P/S Multiple|CABA - Price-to-Revenue Coefficient|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Market Cap to Revenue Theratechnologies, Inc. (THTX)|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|Zura Bio - P/S Multiple|ATYR: Price-to-Revenue Ratio|ADAG: P/S Multiple|Market Cap to Revenue Ikena Oncology|Price-to-Revenue Ratio Shattuck Labs Inc|Price-to-Revenue Ratio EQ|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX: Price-to-Sales Ratio|P/S Multiple ATRA (Atara Bio)|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|INDP (Indaptus Therapeutics) - P/S Multiple|Price-to-Revenue Ratio SCNI|P/S Multiple CALI|Market Cap to Revenue affimed.com AFMD|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Price to Sales|IGMS - Price-to-Revenue Ratio|ITOS: Price-to-Revenue Ratio|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TCBP (TC BioPharm (Holdings) Plc) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
